


### AMENDMENTS TO THE CLAIMS

1. (Original) A pharmaceutical composition for being administered to periodontal pockets, comprising a bisphosphonic acid derivative or a salt thereof, and a base which undergoes liquid-gel phase transition upon contact with physiological body fluid in the periodontal pocket.

2. (Original) The pharmaceutical composition for being administered to periodontal pockets according to claim 1, wherein said bisphosphonic acid derivative or the salt thereof is a methane bisphosphonic acid derivative represented by Formula (I):



[wherein X represents C<sub>1</sub>-C<sub>8</sub> linear or branched alkyl or cycloalkyl (in case of cycloalkyl, the number of carbon atoms is 3 to 8) which is not substituted or which has (a) substituent(s) having nitrogen, oxygen and/or silicon atom(s), phenyl or naphthyl (the phenyl or naphthyl may be substituted by C<sub>1</sub>-C<sub>8</sub> linear or branched alkyl or cycloalkyl (in case of cycloalkyl, the number of carbon atoms is 3 to 8), C<sub>1</sub>-C<sub>8</sub> linear or branched alkoxy, halogen and/or hydroxy); Y represents C<sub>1</sub>-C<sub>8</sub> linear or branched alkyl, trifluoromethyl, C<sub>2</sub>-C<sub>8</sub> linear or branched alkenyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy or halogen (excluding chlorine substituting at *p*- position); m and n independently represent 0, 1, 2 or 3; ••• represents double bond or single bond; A represents -(D)<sub>b</sub>-(CH<sub>2</sub>)<sub>c</sub>- (wherein D represents sulfur, oxygen, NR<sup>5</sup> (wherein R<sup>5</sup> represents hydrogen or

C<sub>1</sub>-C<sub>8</sub> linear or branched alkyl or cycloalkyl (in case of cycloalkyl, the number of carbon atoms is 3 to 8), D binding directly to the methane bisphosphonic acid, c represents an integer of 0 to 3, b represents 0 or 1), or -(CH=CH)<sub>d</sub>-CH= (wherein d represents 0 or 1, and when A is -(CH=CH)<sub>d</sub>-CH=, B does not exist); B represents hydrogen, C<sub>1</sub>-C<sub>8</sub> linear or branched alkyl or cycloalkyl (in case of cycloalkyl, the number of carbon atoms is 3 to 8), hydroxy or 5 trialkylsiloxy (each of the alkyl groups therein is C<sub>1</sub>-C<sub>8</sub> linear or branched alkyl or cycloalkyl (in case of cycloalkyl, the number of carbon atoms is 3 to 8); R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup>, the same or different, represent hydrogen, C<sub>1</sub>-C<sub>8</sub> linear or branched alkyl or cycloalkyl (in case of cycloalkyl, the number of carbon atoms is 3 to 8), or a pharmaceutically acceptable cation] or a hydrate thereof.

3. (Original) The pharmaceutical composition for being administered to periodontal pockets according to claim 1 or 2, wherein X in said Formula (I) represents C<sub>1</sub>-C<sub>8</sub> linear or branched alkyl; Y represents the same meanings as described above; m and n independently represent 0 or 1;  $\cdot \cdot \cdot$  represents single bond; A represents -S-(CH<sub>2</sub>)<sub>c</sub>- (wherein c represents an integer of 0 to 3); B represents hydrogen or C<sub>1</sub>-C<sub>8</sub> linear or branched alkyl; and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> represent the same meanings as in claim 2.

4. (Currently amended) The pharmaceutical composition for being administered to periodontal pockets according to any one of ~~claims 1 to 3~~ claim 1 or 2, wherein said base is at least one polysaccharide.

5. The pharmaceutical composition for being administered to periodontal pockets according to claim 4; wherein said polysaccharide is gellan gum and/or carageenan.

6. (Currently amended) The pharmaceutical composition for being administered to periodontal pockets according to any one of claims 1 to [[5]] 2, which is for therapy of a periodontal disease.

7. (Currently amended) A method for treating periodontal pockets, comprising administering an effective amount of said composition according to any one of claims 1 to [[5]] 2 to a periodontal pocket.

8. (Currently amended) A therapeutic method for a periodontal disease, comprising administering an effective amount of said composition according to any one of claims 1 to [[5]] 2 to a periodontal pocket.

9. (Currently amended) Use of said composition according to any one of claims 1 to [[5]] 2, for the production of a pharmaceutical composition for being administered to periodontal pockets.

10. (Currently amended) Use of said composition according to any one of claims 1 to [[5]] 2, for the production of a pharmaceutical composition for therapy of a periodontal disease.